Does it Matter Whether Canada’s Separate Health Technology Assessment Process for Cancer Drugs has an Economic Rationale?

Detalles Bibliográficos
Autores principales: Hoch, Jeffrey S., Beca, Jaclyn, Sabharwal, Mona, Livingstone, Scott W., Fields, Anthony L. A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2015
Materias:
Letter to the Editor
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4519630/
https://www.ncbi.nlm.nih.gov/pubmed/25939500
http://dx.doi.org/10.1007/s40273-015-0278-7
_version_ 1782383528495808512
author Hoch, Jeffrey S.
Beca, Jaclyn
Sabharwal, Mona
Livingstone, Scott W.
Fields, Anthony L. A.
author_facet Hoch, Jeffrey S.
Beca, Jaclyn
Sabharwal, Mona
Livingstone, Scott W.
Fields, Anthony L. A.
author_sort Hoch, Jeffrey S.
collection PubMed
description
format Online
Article
Text
id pubmed-4519630
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher Springer International Publishing
record_format MEDLINE/PubMed
spelling pubmed-45196302015-08-03 Does it Matter Whether Canada’s Separate Health Technology Assessment Process for Cancer Drugs has an Economic Rationale? Hoch, Jeffrey S. Beca, Jaclyn Sabharwal, Mona Livingstone, Scott W. Fields, Anthony L. A. Pharmacoeconomics Letter to the Editor Springer International Publishing 2015-05-05 2015 /pmc/articles/PMC4519630/ /pubmed/25939500 http://dx.doi.org/10.1007/s40273-015-0278-7 Text en © The Author(s) 2015 Open AccessThis article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/), which permits any noncommercial use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.
spellingShingle Letter to the Editor
Hoch, Jeffrey S.
Beca, Jaclyn
Sabharwal, Mona
Livingstone, Scott W.
Fields, Anthony L. A.
Does it Matter Whether Canada’s Separate Health Technology Assessment Process for Cancer Drugs has an Economic Rationale?
title Does it Matter Whether Canada’s Separate Health Technology Assessment Process for Cancer Drugs has an Economic Rationale?
title_full Does it Matter Whether Canada’s Separate Health Technology Assessment Process for Cancer Drugs has an Economic Rationale?
title_fullStr Does it Matter Whether Canada’s Separate Health Technology Assessment Process for Cancer Drugs has an Economic Rationale?
title_full_unstemmed Does it Matter Whether Canada’s Separate Health Technology Assessment Process for Cancer Drugs has an Economic Rationale?
title_short Does it Matter Whether Canada’s Separate Health Technology Assessment Process for Cancer Drugs has an Economic Rationale?
title_sort does it matter whether canada’s separate health technology assessment process for cancer drugs has an economic rationale?
topic Letter to the Editor
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4519630/
https://www.ncbi.nlm.nih.gov/pubmed/25939500
http://dx.doi.org/10.1007/s40273-015-0278-7
work_keys_str_mv AT hochjeffreys doesitmatterwhethercanadasseparatehealthtechnologyassessmentprocessforcancerdrugshasaneconomicrationale
AT becajaclyn doesitmatterwhethercanadasseparatehealthtechnologyassessmentprocessforcancerdrugshasaneconomicrationale
AT sabharwalmona doesitmatterwhethercanadasseparatehealthtechnologyassessmentprocessforcancerdrugshasaneconomicrationale
AT livingstonescottw doesitmatterwhethercanadasseparatehealthtechnologyassessmentprocessforcancerdrugshasaneconomicrationale
AT fieldsanthonyla doesitmatterwhethercanadasseparatehealthtechnologyassessmentprocessforcancerdrugshasaneconomicrationale

Ejemplares similares